diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM10185diaendo-10185Research ArticleОбзорыReviewОбзор результатов международного наблюдательного исследования EASYDia. Влияние титрации дозы диабетона МВ на эффективность терапии сахарного диабета 2 типаReview of the results of the EASYDia international observational study. The effect of dose titration of diabeton MR on the effectiveness of treatment of type 2 diabeteshttps://orcid.org/0000-0003-3838-8285ТрубицынаНаталья ПетровнаTrubitsynaNatalia Р.

к.м.н., в.н.с.

MD, PhD, leading research associate

trubicina@mail.ruhttps://orcid.org/0000-0002-5057-127XШестаковаМарина ВладимировнаShestakovaMarina V.

д.м.н., профессор, академик РАН

MD, PhD, Professor

nephro@endocrincentr.ru<p>Национальный медицинский исследовательский центр эндокринологии</p>Россия<p>Endocrinology Research Centre</p>Russian Federation201923062019222159164Copyright &#x00A9; Трубицына Н.П., Шестакова М.В., 20192019Трубицына Н.П., Шестакова М.В.Trubitsyna N.Р., Shestakova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/10185

Несмотря на появление новых классов сахароснижающих препаратов, производные сульфонилмочевины (в частности, гликлазид МВ) по-прежнему занимают важное место в алгоритмах лечения сахарного диабета 2 типа (СД2). Крупное наблюдательное международное исследование EASYDia по оценке эффективности гликлазида МВ 60 мг в условиях реальной повседневной клинической практики у лиц с длительным течением СД2, получающих стандартную сахароснижающую терапию, показало, что тактика поэтапной интенсификации терапии, основанная на применении гликлазида МВ 60 мг, позволяет достигать и поддерживать целевые значения гликемии, обеспечивая хорошую переносимость даже в максимальных дозах при низком риске гипогликемий и отсутствии прибавки массы тела.

Although the number of antihyperglycemic agents has expanded significantly, sulfonylureas (in particular gliclazide MR) remain an important option in the treatment algorithms of type 2 diabetes mellitus (DM2). A large observational international study EASYDia in real clinical practice, assessing effectiveness of gliclazide MR 60 mg in patients with long-term DM2 on standard glucose-lowering therapy, showed that step-by-step intensification of therapy with gliclazide MR 60mg allows to achieve and maintain the target values of glycemia, with good tolerability even in maximum doses, low risk of hypoglycemia and no weight gain.

сахарный диабет 2 типагликлазид МВгликемический контрольпереносимостьреальная повседневная практикаtype 2 diabetes mellitusgliclazide MRglycemic controltolerabilityreal-world practiceReferencesAdvance Collaborative Group; Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. doi: https://doi.org/10.1056/NEJMoa0802987Advance Collaborative Group; Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. doi: https://doi.org/10.1056/NEJMoa0802987Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37(8):2359–2365. doi: https://doi.org/10.2337/dc14-0199Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37(8):2359–2365. doi: https://doi.org/10.2337/dc14-0199Zoungas S, Chalmers J, Kengne AP, et al. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract. 2010;89(2):126–133. doi: https://doi.org/10.1016/j.diabres.2010.05.012Zoungas S, Chalmers J, Kengne AP, et al. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract. 2010;89(2):126–133. doi: https://doi.org/10.1016/j.diabres.2010.05.012National Institute for Health and Care Excellence (NICE) Internal Clinical Guidelines Team. Type 2 diabetes in adults (Clinical Guideline Update NG28). London, UK: National Institute for Health and Care Excellence; 2017.National Institute for Health and Care Excellence (NICE) Internal Clinical Guidelines Team. Type 2 diabetes in adults (Clinical Guideline Update NG28). London, UK: National Institute for Health and Care Excellence; 2017.Gordon J, McEwan P, Evans M, et al. Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care-based cohort study, with economic assessment of patient outcomes. Diabetes Obes Metab. 2017;19(5):644–653. doi: https://doi.org/10.1111/dom.12867Gordon J, McEwan P, Evans M, et al. Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care-based cohort study, with economic assessment of patient outcomes. Diabetes Obes Metab. 2017;19(5):644–653. doi: https://doi.org/10.1111/dom.12867Rutten GE, De Grauw WJ, Nijpels G, et al. [NHG-Standaard Diabetes mellitus type 2 (derde herziening). (In Dutch).] Huisarts Wet. 2013;56(10):512–525.Rutten GE, De Grauw WJ, Nijpels G, et al. [NHG-Standaard Diabetes mellitus type 2 (derde herziening). (In Dutch).] Huisarts Wet. 2013;56(10):512–525.Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379. doi: https://doi.org/10.2337/dc12-0413Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379. doi: https://doi.org/10.2337/dc12-0413Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic management of type 2 diabetes: 2016 interim update. Can J Diabetes. 2016;40(6):484–486. doi: https://doi.org/10.1016/j.jcjd.2016.09.003Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic management of type 2 diabetes: 2016 interim update. Can J Diabetes. 2016;40(6):484–486. doi: https://doi.org/10.1016/j.jcjd.2016.09.003World Health Organization. Guidelines on second-and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus. Geneva: World Health Organization; 2018.World Health Organization. Guidelines on second-and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus. Geneva: World Health Organization; 2018.Royal Australian College of General Practitioners (RACGP) and Diabetes Australia. General practice management of type 2 diabetes 2016-2018. East Melbourne, Vic: Royal Australian College of General Practitioners; 2016. 232 p.Royal Australian College of General Practitioners (RACGP) and Diabetes Australia. General practice management of type 2 diabetes 2016-2018. East Melbourne, Vic: Royal Australian College of General Practitioners; 2016. 232 p.SEMDSA 2017 guidelines for the management of type 2 diabetes mellitus. JEMDSA. 2017;22 Suppl 1:S1–S196.SEMDSA 2017 guidelines for the management of type 2 diabetes mellitus. JEMDSA. 2017;22 Suppl 1:S1–S196.Kalra S, Aamir AH, Raza A, et al. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: a consensus statement. Indian J Endocrinol Metab. 2015;19(5):577–596. doi: https://doi.org/10.4103/2230-8210.163171Kalra S, Aamir AH, Raza A, et al. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: a consensus statement. Indian J Endocrinol Metab. 2015;19(5):577–596. doi: https://doi.org/10.4103/2230-8210.163171Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110(3):551–555. doi: https://doi.org/10.1038/bjc.2013.725Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110(3):551–555. doi: https://doi.org/10.1038/bjc.2013.725Ruiz M. Diamicron (gliclazide) MR: the secretagogue with clinical benefits beyond insulin secretion. Medicographia. 2013;35(1):81–89.Ruiz M. Diamicron (gliclazide) MR: the secretagogue with clinical benefits beyond insulin secretion. Medicographia. 2013;35(1):81–89.Шестакова М.В., Викулова О.К. Результаты открытой наблюдательной программы DIAMOND // Сахарный диабет. – 2011. – Т.14. –№3 – С. 96–102. [Shestakova MV, Vikulova OK. The results of open observational trial DIAMOND. Diabetes mellitus. 2011;14(3):96–102. (In Russ).] doi: https://doi.org/10.14341/2072-0351-6232Шестакова М.В., Викулова О.К. Результаты открытой наблюдательной программы DIAMOND // Сахарный диабет. – 2011. – Т.14. –№3 – С. 96–102. [Shestakova MV, Vikulova OK. The results of open observational trial DIAMOND. Diabetes mellitus. 2011;14(3):96–102. (In Russ).] doi: https://doi.org/10.14341/2072-0351-6232Leiter LA, Shestakova MV, Trubitsyna NP, et al. Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation. Diabetes Res Clin Pract. 2016;112:50–56. doi: https://doi.org/10.1016/j.diabres.2015.11.001Leiter LA, Shestakova MV, Trubitsyna NP, et al. Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation. Diabetes Res Clin Pract. 2016;112:50–56. doi: https://doi.org/10.1016/j.diabres.2015.11.001Leiter LA, Shestakova MV, Satman I. Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial. Diabetol Metab Syndr. 2018;10(1):30. doi: https://doi.org/10.1186/s13098-018-0331-8Leiter LA, Shestakova MV, Satman I. Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial. Diabetol Metab Syndr. 2018;10(1):30. doi: https://doi.org/10.1186/s13098-018-0331-8Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. doi: https://doi.org/10.1056/NEJMoa1307684Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. doi: https://doi.org/10.1056/NEJMoa1307684Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334. doi: https://doi.org/10.1056/NEJMoa1515920Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334. doi: https://doi.org/10.1056/NEJMoa1515920White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. doi: https://doi.org/10.1056/NEJMoa1305889White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. doi: https://doi.org/10.1056/NEJMoa1305889Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;374(11):1094. doi: https://doi.org/10.1056/NEJMc1600827Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;374(11):1094. doi: https://doi.org/10.1056/NEJMc1600827Mosenzon O, Leibowitz G, Bhatt DL, et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care. 2017;40(1):69–76. doi: https://doi.org/10.2337/dc16-0621Mosenzon O, Leibowitz G, Bhatt DL, et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care. 2017;40(1):69–76. doi: https://doi.org/10.2337/dc16-0621Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–1588. doi: https://doi.org/10.1161/CIRCULATIONAHA.114.010389Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–1588. doi: https://doi.org/10.1161/CIRCULATIONAHA.114.010389Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. doi: https://doi.org/10.1056/NEJMoa1501352Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. doi: https://doi.org/10.1056/NEJMoa1501352Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi: https://doi.org/10.1056/NEJMoa1607141Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi: https://doi.org/10.1056/NEJMoa1607141Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi: https://doi.org/10.1056/NEJMoa1603827Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi: https://doi.org/10.1056/NEJMoa1603827Neal B, Perkovic V, Mahaffey KW, et al. Canaglilozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi: https://doi.org/10.1056/NEJMoa1611925Neal B, Perkovic V, Mahaffey KW, et al. Canaglilozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi: https://doi.org/10.1056/NEJMoa1611925Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–2498. doi: https://doi.org/10.1007/s00125-018-4729-5Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–2498. doi: https://doi.org/10.1007/s00125-018-4729-5Hassanein M, Abdallah K, Schweizer A. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc Health Risk Manag. 2014;10:319–326. doi: https://doi.org/10.2147/VHRM.S64038Hassanein M, Abdallah K, Schweizer A. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc Health Risk Manag. 2014;10:319–326. doi: https://doi.org/10.2147/VHRM.S64038Clemens KK, McArthur E, Dixon SN, et al. The hypoglycemic risk of glyburide (glibenclamide) compared with modified-release gliclazide. Can J Diabetes. 2015;39 Suppl 4:32–40. doi: https://doi.org/10.1016/j.jcjd.2015.09.087Clemens KK, McArthur E, Dixon SN, et al. The hypoglycemic risk of glyburide (glibenclamide) compared with modified-release gliclazide. Can J Diabetes. 2015;39 Suppl 4:32–40. doi: https://doi.org/10.1016/j.jcjd.2015.09.087Ibrahim M, Abu Al Magd M, Annabi FA, et al. Recommendations for management of diabetes during Ramadan: update 2015. BMJ Open Diabetes Res Care. 2015;3(1):e000108. doi: https://doi.org/10.1136/bmjdrc-2015-000108Ibrahim M, Abu Al Magd M, Annabi FA, et al. Recommendations for management of diabetes during Ramadan: update 2015. BMJ Open Diabetes Res Care. 2015;3(1):e000108. doi: https://doi.org/10.1136/bmjdrc-2015-000108Ali S, Davies MJ, Brady EM, et al. Guidelines for managing diabetes in Ramadan. Diabet Med. 2016;33(10):1315–1329. doi: https://doi.org/10.1111/dme.13080Ali S, Davies MJ, Brady EM, et al. Guidelines for managing diabetes in Ramadan. Diabet Med. 2016;33(10):1315–1329. doi: https://doi.org/10.1111/dme.13080Aravind SR, Al Tayeb K, Ismail SB, et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Curr Med Res Opin. 2011;27(6):1237–1242. doi: https://doi.org/10.1185/03007995.2011.578245Aravind SR, Al Tayeb K, Ismail SB, et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Curr Med Res Opin. 2011;27(6):1237–1242. doi: https://doi.org/10.1185/03007995.2011.578245Mbanya JC, Al-Sifri S, Abdel-Rahim A, Satman I. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: a meta-analytical approach. Diabetes Res Clin Pract. 2015;109(2):226–232. doi: https://doi.org/10.1016/j.diabres.2015.04.030Mbanya JC, Al-Sifri S, Abdel-Rahim A, Satman I. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: a meta-analytical approach. Diabetes Res Clin Pract. 2015;109(2):226–232. doi: https://doi.org/10.1016/j.diabres.2015.04.030

The authors declare that there are no conflicts of interest present.